Skillz And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

The Dow Jones closed higher by around 80 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Skillz

• The Trade: Skillz Inc. SKLZ CEO Andrew Paradise acquired a total 1,500,000 shares an average price of $0.56. To acquire these shares, it cost around $836.25 thousand.
• What’s Happening: Skillz reported better-than-expected Q4 results.
• What Skillz Does: Skillz Inc is a mobile game development company. Its platform helps developers build multi-million dollar franchises by enabling social competition in their games.

MetaWorks Platforms

• The Trade: MetaWorks Platforms, Inc. MWRK Director Shelly Marie Murphy acquired a total of 500,000 shares at an average price of $0.05. The insider spent around $25 thousand to buy those shares. The company’s President also purchased the company’s shares.
• What’s Happening: MetaWorks Platforms named Entertainment and Technology Entrepreneur Michael Williams to its advisory board.
• What MetaWorks Platforms Does: MetaWorks Platforms Inc is a full-service blockchain and web development platform provider.

Check This Out: These 3 Consumer Stocks With Over 5% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

Gossamer Bio

• The Trade: Gossamer Bio, Inc. GOSS COO, CFO Bryan Giraudo acquired a total of 55,000 shares at an average price of $1.02. To acquire these shares, it cost around $56.09 thousand.
• What’s Happening: The FDA placed a partial clinical hold on Gossamer Bio’s all trials of GB5121 in response to serious adverse events observed in the Phase 1b/2 STAR-CNS study, including atrial fibrillation, a sudden death event, and a fatal intracranial hemorrhage.
• What Gossamer Bio Does: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology.

Don’t forget to check out our premarket coverage here